Additional Nucleotide Derivatives of Mitosenes. Synthesis and Activity against Parental and Multidrug Resistant L1210 Leukemia

Bhashyam S. Iyengar, William A. Remers, Robert T. Dorr

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Cytidine 5′-monophosphate and 5′-αrα-CMP conjugates of 2,7-diaminomitosene, with the phosphate groups linked to C-1, were prepared by treating mitomycin C with the appropriate nucleotides. 5’′-UMP conjugates were prepared from mitomycin A, 7 (M-83), and 8 (BMY-25282) by similar procedures. A conjugate could not be prepared from mitomycin C and 6-MPRP, but a sulfur-linked derivative was made with 6-MP ribonucleoside. The corresponding l-hydroxy-2-aminomitosenes were prepared from the parent mitomycin analogues for structure-activity comparisons. All compounds were tested against L1210 murine leukemia in the MTT tetrazolium dye assay. In general, the conjugates were less potent than the parent mitomycins; however 5′-αrα-CMP conjugate 14 derived from mitomycin C was more potent than the parent compound or any mitomycin tested except mitomycin A. It also was more potent than ara-C. This result establishes the value of this approach to prodrugs, at least in cell culture. Against a multidrug-resistant L1210 cell line, all of the conjugates derived from mitomycin C were more potent than the parent compound. 6-Mercaptopurine ribonucleoside conjugate 15 was more active against the resistant cells than it was against the parental cell line.

Original languageEnglish (US)
Pages (from-to)1947-1951
Number of pages5
JournalJournal of Medicinal Chemistry
Volume34
Issue number7
DOIs
StatePublished - Jul 1 1991
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Additional Nucleotide Derivatives of Mitosenes. Synthesis and Activity against Parental and Multidrug Resistant L1210 Leukemia'. Together they form a unique fingerprint.

Cite this